期刊文献+

慢性肺部疾病患者接种23价肺炎链球菌多糖疫苗后抗荚膜多糖抗体的特异性 被引量:1

Specificity of antibody response to 23-valent pneumococcal polysaccharide vaccine in patients with chronic pulmonary diseases
原文传递
导出
摘要 目的探讨慢性肺部疾病患者接种23价肺炎链球菌多糖疫苗(PPV)后血清中抗肺炎链球菌荚膜多糖(CPS)IgG抗体的特异性。方法以39例慢性肺部疾病患者为研究对象,分别用第二代和特异性更高的第三代ELISA测定疫苗接种前、后血清中的肺炎链球菌6B、19F和23F三种血清型的特异性IgG抗体浓度。结果用第三代ELISA测得的患者血清中血清型特异性IgG抗体水平比用第二代ELISA测得的抗体水平显著降低。无论是PPV接种前的自然感染,还是PPV接种后的主动免疫,慢性肺部疾病患者血中产生的抗CPS-IgG中都有大约一半的非特异性抗体。结论 PPV接种并不能提高慢性肺部疾病患者血中的特异性抗CPS-IgG的比例。 Objective To study the specificity of the serotype-specific IgG in the sera of patients with chronic pulmonary diseases(CPD)after pneumococcal vaccination.Methods Serotype-specific IgG concentrations were measured by the second and third(with more specificity)generation ELISA for serotype 6B,19F and 23F in 39 CPD patients after vaccinated with 23-valent pneumococcal polysaccharide vaccine(PPV).Results The serotype-specific IgG levels measured by the third-generation ELISA were much lower than those by the second-generation ELISA.About half of the anti-CPS IgG in the sera of CPD patients was non-specific antibody whether natural infection or vaccination.Conclusion PPV can not improve the proportion of serotype-specific antibodies in the sera of patients with CPD.
作者 陈蒙 赵德育
出处 《江苏医药》 CAS CSCD 北大核心 2010年第17期2002-2004,共3页 Jiangsu Medical Journal
关键词 肺炎链球菌多糖疫苗 慢性肺部疾病 血清型特异性IgG Pneumococcal polysaccharide vaccine Chronic pulmonary diseases Serotype-specific IgG
  • 相关文献

参考文献11

  • 1Sethi S. New developments in the pathogenesis of acute exacerbation of chronic obstructive pulmonary disease [J]. Curt Opin Infect Dis,2004,17(2) :113-119. 被引量:1
  • 2Centers for Disease Control and Prevention. Prevention of pneumococcal disease:recommendations of the advisory com- mittee on immunization practices (ACIP) [J]. Morb Mortal Wkly Rep, 1997,46 (RR-8) :1-24. 被引量:1
  • 3Musher DM, Chapman AJ, Goree A, et al. Natural and vaccine-related immunity to Streptococcus pneumoniae[J]. J Infect Dis, 1986,154(2) :245-256. 被引量:1
  • 4Davis AL, Aranda CP, Schiffman G, et al. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease [J]. Chest,1987,92 (2) :204-212. 被引量:1
  • 5Saito W, Nagai H, Suzuki J, et al. Capsular polysaccharide antibodies after pneumococcal polysaccharide vaccination in patients with chronic respiratory disease[J]. Nihon Kokyuki Gakkai Zasshi, 2005,43(5) :277-282. 被引量:1
  • 6de RouxA, SchmidtN, Rose M,et al. Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids [J]. Respir Med, 2004, 98 (12): 1187-1194. 被引量:1
  • 7Concepcion NF, Frasch CE. Pneumococcal type 22F polysaccharicle absorption improves the specificity of a pneumococcalpolysaccharide enzyme-linked immunosorbent assay[J]. Clin Diagn Lab Immunol, 2001,8(2) : 266-272. 被引量:1
  • 8Oishi K, Yoshimine H, Watanabe H, et al. Drug-resistant genes and serotypes of pneumococcal strains of communityacquired pneumonia among adults in Japan[J]. Respirology, 2006,11(4) :429-436. 被引量:1
  • 9Fraseh CE, Concepcion NF. Specificity of human antibodies reactive with pneumocoecal C polysaccharide [J]. Infect Immun, 2000,68(4) :2333-2337. 被引量:1
  • 10Musher DM, Watson DA, Baughn RE. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection[J]?J Infect Dis, 1990, 161(4) :736-740. 被引量:1

同被引文献13

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部